Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 9027484, 8 pages
http://dx.doi.org/10.1155/2016/9027484
Research Article

Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer’s Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan

1Department of Endocrinology and Metabolism, Tungs’ Taichung MetroHarbor Hospital, Taichung 435, Taiwan
2Department of Information Management, Hsing Wu University, New Taipei City, Taiwan
3Department of Biomedical Informatics, Asia University, Taichung 413, Taiwan
4Department of Computer Science and Information Engineering, National Central University, Chungli, Taiwan

Received 11 July 2016; Accepted 29 September 2016

Academic Editor: Dilek Yavuz

Copyright © 2016 Cheng-Wei Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Cukierman, H. C. Gerstein, and J. D. Williamson, “Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies,” Diabetologia, vol. 48, no. 12, pp. 2460–2469, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K.-C. Wang, L.-C. Woung, M.-T. Tsai, C.-C. Liu, Y.-H. Su, and C.-Y. Li, “Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study,” Neuroepidemiology, vol. 38, no. 4, pp. 237–244, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Ahtiluoto, T. Polvikoski, M. Peltonen et al., “Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study,” Neurology, vol. 75, no. 13, pp. 1195–1202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Arvanitakis, R. S. Wilson, J. L. Bienias, D. A. Evans, and D. A. Bennett, “Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function,” Archives of Neurology, vol. 61, no. 5, pp. 661–666, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Janson, T. Laedtke, J. E. Parisi, P. O'Brien, R. C. Petersen, and P. C. Butler, “Increased risk of type 2 diabetes in Alzheimer disease,” Diabetes, vol. 53, no. 2, pp. 474–481, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. J. M. Chen, C. W. Chang, T. H. Chang, C. C. Hsu, J. T. Horng, and W. H.-H. Sheu, “Effects of statins on incident dementia in patients with type 2 DM: a population-based retrospective cohort study in Taiwan,” PLoS ONE, vol. 9, Article ID e88434, 2014. View at Publisher · View at Google Scholar
  7. J. C. S. Breitner, B. A. Gau, K. A. Welsh et al., “Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study,” Neurology, vol. 44, no. 2, pp. 227–232, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. J. B. Rich, D. X. Rasmusson, M. F. Folstein, K. A. Carson, C. Kawas, and J. Brandt, “Nonsteroidal anti-inflammatory drugs in Alzheimer's disease,” Neurology, vol. 45, no. 1, pp. 51–55, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. G. A. Broe, D. A. Grayson, H. M. Creasey et al., “Anti-inflammatory drugs protect against Alzheimer disease at low doses,” Archives of Neurology, vol. 57, no. 11, pp. 1586–1591, 2000. View at Google Scholar · View at Scopus
  10. J. C. Anthony, J. C. S. Breitner, P. P. Zandi et al., “Reduced prevalence of AD in users of NSAIDS and H2 receptor antagonists: the Cache County study,” Neurology, vol. 54, no. 11, pp. 2066–2071, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. P. P. Zandi, J. C. Anthony, K. M. Hayden, K. Mehta, L. Mayer, and J. C. S. Breitner, “Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study,” Neurology, vol. 59, no. 6, pp. 880–886, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Cornelius, J. Fastbom, B. Winblad, and M. Viitanen, “Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population,” Neuroepidemiology, vol. 23, no. 3, pp. 135–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. A. Szekely, J. C. S. Breitner, A. L. Fitzpatrick et al., “NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type,” Neurology, vol. 70, no. 1, pp. 17–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Szekely, R. C. Green, J. C. S. Breitner et al., “No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies,” Neurology, vol. 70, no. 24, pp. 2291–2298, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. Nilsson, B. Johansson, S. Takkinen et al., “Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged > or =80 years,” European Journal of Clinical Pharmacology, vol. 59, no. 4, pp. 313–319, 2003. View at Google Scholar
  16. S. R. Waldstein, C. R. Wendell, S. L. Seliger, L. Ferrucci, E. J. Metter, and A. B. Zonderman, “Nonsteroidal anti-inflammatory drugs, aspirin, and cognitive function in the Baltimore longitudinal study of aging,” Journal of the American Geriatrics Society, vol. 58, no. 1, pp. 38–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Arvanitakis, F. Grodstein, J. L. Bienias et al., “Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology,” Neurology, vol. 70, no. 23, pp. 2219–2225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. S. Henderson, A. F. Jorm, H. Christensen, P. A. Jacomb, and A. E. Korten, “Aspirin, anti-inflammatory drugs and risk of dementia,” International Journal of Geriatric Psychiatry, vol. 12, no. 9, pp. 926–930, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. NHIRD Introduction to the National Health Insurance Research Database (NHIRD), Taiwan.
  20. I.-C. Chien, Y.-J. Chou, C.-H. Lin, S.-H. Bih, P. Chou, and H.-J. Chang, “Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996–2001,” Psychiatry and Clinical Neurosciences, vol. 58, no. 6, pp. 611–618, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. C.-W. Chang, V. C. Kok, T.-C. Tseng, J.-T. Horng, and C.-E. Liu, “Diabetic patients with severe sepsis admitted to intensive care unit do not fare worse than non-diabetic patients: a nationwide population-based cohort study,” PLoS ONE, vol. 7, no. 12, Article ID e50729, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Beard, S. C. Waring, P. C. O'Brien, L. T. Kurland, and E. Kokmen, “Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case- control study in Rochester, Minnesota, 1980 through 1984,” Mayo Clinic Proceedings, vol. 73, no. 10, pp. 951–955, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. W. F. Stewart, C. Kawas, M. Corrada, and E. J. Metter, “Risk of Alzheimer's disease and duration of NSAID use,” Neurology, vol. 48, no. 3, pp. 626–632, 1997. View at Publisher · View at Google Scholar · View at Scopus
  24. P. M. Doraiswamy, A. Krishen, F. Stallone et al., “NSAIDs and cognition in Alzheimer's disease,” Neurology, vol. 46, no. 4, p. 1194, 1996. View at Google Scholar · View at Scopus
  25. F. Landi, M. Cesari, G. Onder, A. Russo, S. Torre, and R. Bernabei, “Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients,” American Journal of Geriatric Psychiatry, vol. 11, no. 2, pp. 179–185, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. T. M. Karplus and K. G. Saag, “Nonsteroidal anti-inflammatory drugs and cognitive function: do they have a beneficial or deleterious effect?” Drug Safety, vol. 19, no. 6, pp. 427–433, 1998. View at Publisher · View at Google Scholar · View at Scopus